Acute Myeloid Leukemia (AML)- NPM1 gene Mutations
Understanding Acute Myeloid Leukemia (AML)- NPM1 gene Mutations
What is Acute Myeloid Leukemia (AML)- NPM1 gene Mutations?
Acute Myeloid Leukemia (AML)- NPM1 Gene Mutations analysis is done using highly sensitive and specialized molecular assays. These include real-time polymerase chain reaction (RT-PCR), Sanger sequencing, pyrosequencing (Pyr), and high-resolution melting (HRM) curve analysis.
People who have acute myeloid leukaemia or AML with a normal karyotype (chromosomal makeup) make a significant part of the cytogenetic group of the condition. Therefore, it is crucial to identify the markers (prognostic) that predict the outcomes to the patients more accurately.
In patients with acute myeloid leukaemia and normal cytogenetics, several genes, including NPM1 (nucleophosmin 1), FLT3 (FMS-like tyrosine kinase 3), and CEBPA (CCAAT/enhancer-binding protein alpha), play a vital role in terms of prognostic significance.
What is Acute Myeloid Leukemia (AML)- NPM1 gene Mutations used for?
NPM1 gene testing is done to locate the specific gene in a person with AML. The presence of NPM1 in people with the FLT3 ligand, suggests a hopeful prognosis. This means that these people are more likely to recover from AML than others.
Interpreting Acute Myeloid Leukemia (AML)- NPM1 gene Mutations results
Interpretations
The results can either be positive or negative. A positive result indicates that the person does have a NPM1 gene mutation. However, a negative result indicates the absence of such a mutation in the gene strain.
Other tests
